Vol. 21/No. 13

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

Investigators are working on a new generation of therapies that activate CD40, an immune checkpoint that helps promote an antitumor response by boosting T-cell–stimulatory signals.

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

The growing use of genomic profiling technologies will help promote the development of anticancer therapies based on molecular features of a tumor rather than the body site of origin.

Lifleucel, a TIL therapy, is being investigated in patients with metastatic melanoma.

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

Suresh S. Ramalingam, MD, discusses the combination of nivolumab and ipilimumab in metastatic non–small cell lung cancer.

Precision medicine should be seen as being synergistic―or at a minimum additive―to population medicine.